A new study has compared the effects of varied doses ofpsilocybin and LSD for the first time. These two popular psychedelics have been of increasing interest in clinical research. The new paper, which detailed a double-blinded, randomized and placebo-controlled study of 28 healthy volunteers, compared the impact of placebo, LSD (100 and 200g) and psilocybin (15 and 30mg). The study was a collaboration between the Liechti Lab at Switzerlands University Hospital Basel and MindMed, an established player in the psychedelics drug development industry.
Technology Networks caught up with Rob Barrow, CEO of MindMed, to discuss the findings in more detail and explore pressing issues around blinding in psychedelic drug development.
Barrow spent 10 years as the chief operating officer of a clinical stage private pharma company before joining the psychedelic non-profit Usona Institute, followed by a move to MindMed in 2020. Barrow says that his vision for MindMed was of a psychedelics company that can operate at scale and juggle multiple assets. It's an ambitious goal. In this interview, he discusses how this aim has been realized in 2022.
Ruairi J Mackenzie (RM): How are doses in psychedelic drug studies decided upon and measured?
Rob Barrow (RB): As in most drug development programs, dosing is one of the key aspects you need to fully characterize throughout early development. When you go into your pivotal phase III studies, you need to have your dose nailed down. There are a number of elements that can factor into dosing on an individual basis, but you're arriving at a dose that you feel is reliably going to induce the pharmacology that you want, to lead to the clinical outcomes that you're seeking to provide to patients.
When we think about dosing with psychedelics, there has been, fortunately, decades of research to well characterize the pharmacokinetics and dynamics and we really have a good understanding of how those interactions play out.
To have a drug that you can bring out to market at scale, you typically end up at a fixed dose regimen unless there's a particular concern, often more of a concern for safety, which tends to not be the case with this drug class. Most of the studies look at metabolic phenotyping and genotyping and drug-drug interactions with LSD; all these things are important in terms of labeling. But often it's not the case that they're labeled for an efficacy or pharmacodynamic reason, they're labeled because of safety. When you think about psychedelics, at this point we feel like we're confident enough in the safety that we are aiming for a fixed dose regimen.
We have launched a phase IIb dose optimization study of LSD. That's really to explore which of those fixed doses reliably gives you the activity that you're seeking to generate both acutely, but also more importantly, in terms of clinical outcomes over the course of several weeks.
RM: You compared LSD and psilocybin doses in a new study. What were the key findings?
RB: The key finding is that LSD is much more potent than psilocybin (which we knew previously) but also that it does appear to induce the same acute psychoactivity and acute perceptual effects as psilocybin. What we don't know this is the key question that remains from this work what we aren't certain of is whether that acute activity directly modulates the clinical response. Whether the acute, perceptual effects are directly causative to antidepressant or anxiolytic effects of these molecules. Nonetheless, we certainly think that this study provides a solid evidence base to allow us to read across the assets.
As we look at data from psilocybin, it gives us increased confidence that we can learn from those results and that they would be applicable to LSD, for instance, which gives us an enormous additional opportunity to learn from research outside of our own programs. And it continues to de-risk our approach and give us more opportunities for expansion of our label and where we might go with marketing one day if we get these therapies approved.
RM: Were these results surprising to you?
RB: It wasnt terribly surprising, given the thousands of patients that have been administered LSD and psilocybin, and anecdotally, you can certainly look at the evidence and say, these are going to behave similarly. But it's important to definitively establish these things. Having scientific evidence to link the two is much more valuable than just anecdotal observation. At the end of the day, its not particularly surprising that there's quite similar activity.
One remaining question is, based on the differences between LSD and psilocybin, and based on the doses that we are exploring between the two molecules, does LSD more reliably induce a certain response at a certain dose? There's a lot more to be discovered about that translation in terms of clinical activity.
This was not done in a population with a diagnosis. We need to understand if there's a similar response in the clinic or how they differentiate. Some of the observational evidence we have from our colleagues who have been working with LSD for a long time is that it very well may be even better at treating the clinical outcomes. Now, we have to prove that.
RM: Theres been a lot of discussion in the field recently about the issue of blinding in clinical trials. In your new study, which was double-blinded, participants were able to guess whether they were taking a drug or a placebo96% of the time. What are the ways forward to try and minimize these issues with blinding?
RB: Its a fascinating topic, I've personally had a lot of interesting engagement, both with researchers and the FDA about this. The FDA and other researchers have preferences in terms of what we're using as control conditions; niacin has been offered up many times, some studies have used diphenhydramine. At the core, the reality is that it is going to be very difficult to fully blind LSD or psilocybin in a two-armed randomized controlled study. We're doing this study with four active doses of LSD plus a placebo. That probably gives you the best quality of the blind if you're looking at dose response, because it's going to be harder to differentiate 50 g from 100 g or 200 g, and 100 g from 200 g. That gives you some complexity that will aid in blinding, but in a two-arm study, it's going to be very difficult.
That said, it's also important for us to not forget that this is not a unique problem to psychedelics. If you look at think of any other CNS-active drug, very often, there is a clear perceptual effect that is going to make it more difficult to blind.
That may be more profound with psychedelics. But consider ketamine, which is a dissociative agent. If you look at the adverse event tables for esketamine versus placebo in the esketamine approval [esketamine is one of the two molecules that make up the racemic mixture of ketamine and was approved by the FDA for treatment resistant depression in 2019], the rate of dissociation in the esketamine arm was many-fold higher than in the placebo group.
RM: Two years is a long time in psychedelics research how do you feel MindMed has moved closer to your goals of making psychedelic research more high-throughput since you joined?
RB: Weve been building substantially over the last year. When I came into the organization, we had only about 10 employees and now we're at about six times that. We've been bringing in the talent and the people from pharma who know how to build big organizations and how to take on challenges in a scalable way and take on multiple programs at the same time. We have been absolutely delivering on that vision internally. In drug development, clinical trials do take a long time, this is just the reality of any development program is that a single trial can often take several years. Were still in a phase where we're continuing to build and have announced new programs over the last year. We also have a number of the studies with our collaborators in the Liechti lab at University Hospital Basel. There are a number of studies they have ongoing with LSD and other indications with other molecules. These give us good evidence to make decisions about how well continue to grow and how we think about potential label expansion and new programs. All of that has been progressing very well.
As we look out over the next year or two years, there are going to be many data sets coming out that are going to be quite informative to us and to the wider world about where the potential lies with LSD and where we think other molecules may fit into the pipeline.
We added a program in the second half of last year, which is the R-enantiomer of MDMA for treatment of autism spectrum disorder. We're making sure to remain laser focused on executing what is in front of us and what we've already taken on, but we are continuing to see an enormous opportunity and one that spans far beyond just a single asset and a single indication and we're continuing to make advancements across all our programs to achieve that goal.
Rob Barrow was speaking to Ruairi J Mackenzie, Senior Science Writer for Technology Networks
Read the rest here:
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]